Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Ramm Pharma ( (TSE:RAMM) ) has provided an announcement.
RAMM Pharma Corp. is considering the sale of its subsidiary, Canapar Corp., and its facility in Italy as part of its strategy to streamline operations and focus on core businesses. This potential sale is aimed at enhancing shareholder value and ensuring long-term company sustainability. However, there is no guarantee that a sale will occur, and updates will be provided as the process progresses.
More about Ramm Pharma
RAMM Pharma is a company engaged in cannabinoid pharmacology and product formulation for cannabis-based pharmaceuticals and hemp-based products. It operates a diversified international production and sales platform, with a significant presence in Uruguay where it develops and sells medically registered cannabinoid pharmaceutical products in various Latin American countries. The company also has operations in Europe, particularly in Italy and Poland, and includes subsidiaries like Canapar Corp. and HemPoland.
YTD Price Performance: 0%
Average Trading Volume: 146,334
Technical Sentiment Consensus Rating: Buy
Current Market Cap: C$1.79M
See more data about RAMM stock on TipRanks’ Stock Analysis page.